Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.

Also Known As:

Networked: 2153 relevant articles (90 outcomes, 348 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Voelkel, Norbert F: 21 articles (03/2015 - 05/2002)
2.	Jain, Rakesh K: 18 articles (04/2015 - 01/2006)
3.	Kim, Sinil: 17 articles (08/2015 - 11/2007)
4.	Hicklin, Daniel J: 17 articles (09/2008 - 04/2002)
5.	Escudier, Bernard: 13 articles (11/2015 - 08/2005)
6.	Backer, Joseph M: 13 articles (12/2014 - 09/2005)
7.	Rini, Brian I: 12 articles (11/2015 - 01/2006)
8.	Duda, Dan G: 12 articles (04/2015 - 08/2002)
9.	Ellis, Lee M: 12 articles (04/2009 - 04/2002)
10.	Motzer, Robert J: 11 articles (11/2015 - 01/2006)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2015 - "In the last two decades new drugs that oppose the effects of vascular endothelial growth factor receptor (VEGFR), and thus angiogenesis, have considerably improved treatment of solid tumors. " 07/22/2008 - "The simultaneous targeting of both endothelial cells and pericytes via inhibition of VEGF receptor (VEGFR) and PDGFbeta receptor (PDGFRbeta) signaling, respectively, has been proposed to enhance the efficacy of antiangiogenic tumor therapy. " 09/01/2003 - "Inhibition of the vascular endothelial growth factor receptor (VEGFR) has been shown to improve the radiation response of several experimental tumors. " 09/01/2015 - "Recently, a first clinical grade ultrasound contrast agent (BR55), targeted at a molecule expressed in neoangiogenesis (vascular endothelial growth factor receptor type 2; VEGFR2) has been introduced and safety and feasibility of VEGFR2-targeted ultrasound imaging is being explored in first inhuman clinical trials in various cancer types. " 06/01/2009 - "Recent studies suggest that vascular endothelial growth factor receptor (VEGFR) 1-positive hematopoietic progenitor cells precede the arrival of tumor cells and form clusters that may portend sites of future metastatic disease. "
2.	Renal Cell Carcinoma (Grawitz Tumor) 04/01/2014 - "Recent studies have suggested efficacy of combined Ang and vascular endothelial growth factor receptor (VEGFR) inhibition for patients with metastatic renal cell carcinoma (mRCC). " 01/01/2015 - "Based on extensive preclinical data and abundant evidence for clinical activity, vascular endothelial growth factor receptor (VEGFR) inhibitors are currently standard of care for metastatic renal cell carcinoma (mRCC). " 02/01/2014 - "Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma." 07/01/2013 - "Over the past several years, the dominant paradigm in drug development for metastatic renal cell carcinoma (mRCC) has been to more selectively and potently target moieties such as the vascular endothelial growth factor receptor. " 02/01/2012 - "Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report."
3.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2006 - "Oral agents directed toward VEGF receptor signaling are in advanced development, but none to date has proven beneficial in phase III trials in advanced colorectal cancer. " 03/01/2013 - "Emerging VEGF-receptor inhibitors for colorectal cancer." 11/01/2010 - "The VEGF receptor 1 (VEGFR-1) is a regulatory receptor which is shredded into plasma of patients with colorectal cancer. " 09/01/2009 - "Quantitative analysis of vascular endothelial growth factor receptors 1 and 2 in colorectal cancer." 09/01/2009 - "Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer."
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/01/2010 - "Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy." 11/01/2015 - "Prognostic and predictive ability of circulating vascular endothelial growth factor (VEGF), stromal derived factor (SDF)-1α and soluble VEGF receptors (sVEGFR) 2 and 3, were evaluated in non-small cell lung cancer (NSCLC) patients enrolled in NCIC Clinical Trials Group BR. " 06/01/2015 - "Recognition of the vascular endothelial growth factor (VEGF) pathway as a key mediator of angiogenesis has led to the clinical study of several VEGF and VEGF receptor (VEGFR) targeted therapies in non-small-cell lung cancer (NSCLC). " 03/01/2012 - "The objective of this multicenter, prospective uncontrolled phase II trial was to determine efficacy, safety and tolerability of vatalanib, an oral angiogenesis inhibitor targeting all known vascular endothelial growth factor receptors, in the second-line treatment of non-small-cell lung cancer (NSCLC). " 08/10/2009 - "This phase II study evaluated efficacy and safety of single-agent axitinib, an oral, potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, in patients with advanced non-small-cell lung cancer (NSCLC). "
5.	Glioblastoma (Glioblastoma Multiforme) 04/28/2015 - "VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner." 05/01/2014 - "Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning." 05/01/2006 - "AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma." 09/15/2001 - "Using an orthotopic intracerebral model, we investigated whether systemic treatment with DC101, a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR)-2, could inhibit angiogenesis and the growth of human glioblastoma cells in severe combined immunodeficient mice. " 08/01/2001 - "The related antibody DC-101 provided proof-of-principle that an anti-VEGF receptor antibody could strongly inhibit tumor growth and even cause tumor regression with the glioblastoma tumor cell line, GBM18 [388236]. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Protein-Tyrosine Kinases (Tyrosine Kinase)
3.	Phosphotransferases (Kinase)
4.	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)
5.	sunitinib (Sutent)
6.	4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
7.	sorafenib (BAY 43-9006)
8.	Epidermal Growth Factor Receptor (EGF Receptor)
9.	bevacizumab
10.	vatalanib (PTK787)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy
3.	Heterologous Transplantation (Xenotransplantation)
4.	Homologous Transplantation (Allograft)
5.	Combination Drug Therapy (Combination Chemotherapy)